Abstract:Glycogen storage disease type VI (GSD-VI; also known as Hers disease, liver phosphorylase deficiency) is caused by mutations in the gene coding for glycogen phosphorylase (PYGL) leading to a defect in the degradation of glycogen. Since there are only about 40 patients described in literature, our knowledge about the course of the disease is limited. In order to evaluate the long-term outcome of patients with GSD-VI, an observational retrospective case study of six patients was performed at the University Children's Hospital Zurich. The introduction of small, frequent meals as well as cornstarch has led to normal growth in all patients and to normalization of liver transaminases in most patients. After starting the dietary regimen, there were no signs of hypoglycemia. However, three of six patients showed persistent elevation of triglycerides. Further, we identified four novel pathogenic PYGL mutations and describe here their highly variable impact on phosphorylase function.Conclusions: After establishing the diagnosis, dietary treatment led to metabolic stability and to prevention of hypoglycemia. Molecular genetics added important information for the understanding of the clinical variability in this disease. While outcome was overall excellent in all patients, half of the patients showed persistent hypertriglyceridemia even after initiating treatment.<table class="a-plus-plus table default-table float-no id-taba"><tbody class="a-plus-plus tbody"><tr class="a-plus-plus row"><td class="a-plus-plus entry nameend-c2 namest-c1">What is Known:• Glycogen storage disease type VI (GSD-VI) is a metabolic disorder causing a defect in glycogen degradation. Dietary treatment normally leads to metabolic stability and prevention of hypoglycemia.• However, our knowledge about the natural course of patients with GSD-VI is limited.</td></tr><tr class="a-plus-plus row"><td class="a-plus-plus entry nameend-c2 namest-c1">What is New:• While outcome was overall excellent in all patients, half of the patients showed persistent hypertriglyceridemia even after initiating treatment.• Molecular genetics added important information for the understanding of the clinical variability in this disease.</td></tr></tbody></table>

Glycogen storage diseases with liver involvement: a literature review of GSD type 0, IV, VI, IX and XI

Hepatic glycogen storage diseases type 0, VI and IX: description of an italian cohort

Glycogen storage diseases: New perspectives

Glycogen storage diseases: An update

Pathobiology of the Hepatic Glycogen Storage Diseases

Endocrine involvement in hepatic glycogen storage diseases: pathophysiology and implications for care

Update on glycogen storage disease: primary hepatic involvement

Glycogen Storage Diseases: A Brief Review and Update on Clinical Features, Genetic Abnormalities, Pathologic Features, and Treatment

The Phenotypic and Genetic Spectrum of Glycogen Storage Disease Type VI

Glycogen storage diseases: Diagnosis, treatment and outcome

Narrative review of glycogen storage disorder type III with a focus on neuromuscular, cardiac and therapeutic aspects

Glycogen Storage Disease: Clinical, Biochemical, and Molecular Heterogeneity

Gene Therapy for Glycogen Storage Diseases

A retrospective longitudinal study and comprehensive review of adult patients with glycogen storage disease type III

Report of 7 cases of glycogen storage disease type VI and type IXa

Glycogen Storage Disease in Adults

Hepatic mitochondrial dysfunction is a feature of Glycogen Storage Disease Type Ia (GSDIa)

Glycogen storage disease type VI: clinical course and molecular background

Glycogen Storage Disease Type I and Bone: Clinical and Cellular Characterization

Glycogen storage disease type IX: High variability in clinical phenotype

Genotypic and phenotypic features of 39 Chinese patients with glycogen storage diseases type I, VI, and IX